Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (156)
ARTG (126)
Prescription medicine registration (23)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)

Date

2024 (120)
2023 (16)
2022 (13)
2021 (68)
2020 (23)
2019 (11)
2018 (6)
2017 (8)
2016 (25)
2015 (9)
2012 (2)
2011 (4)
2010 (1)
2006 (3)
2002 (7)
1995 (2)

Results for "[search-keyword]"

Search

Sponsor content

318 result(s) found, displaying 191 to 200

EPIRUBE epirubicin hydrochloride 20 mg/10 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EPIRUBE epirubicin hydrochloride 200 mg/100 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EPIRUBE epirubicin hydrochloride 150 mg/75 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EPIRUBE epirubicin hydrochloride 10 mg/5 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
BLENAMAX bleomycin sulfate 15000IU powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
RAPILYSIN reteplase 10U powder for injection vial and water for injections diluent syringe composite pack Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EMTHEXATE methotrexate 1g/10mL (as sodium) injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EMTHEXATE methotrexate 50mg/2mL (as sodium) injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EMTHEXATE methotrexate 5mg/2mL (as sodium) injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
NUVIGIL armodafinil 250 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd

Pages

First page
Previous page
…
Page 16
Page 17
Page 18
Page 19
Current page 20
Page 21
Page 22
Page 23
Page 24
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.